Brought to you by 
Thermo Fisher acquires CDMO Patheon in megadeal valued at nearly $7.2bn
May 2017
Executive Summary
Drug development/delivery company Thermo Fisher Scientific Inc. acquired leading contract development and manufacturer Patheon NV for $35 per share (31% premium to prior 10 day trading average) or nearly $7.2bn in enterprise value (including $2bn in net debt).
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Services
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Thermo Fisher acquires CDMO Patheon in megadeal valued at nearly $7.2bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice